Neoadjuvant Target Therapy in Her-2 Positive Breast Cancer Dr. Khaled Abulkhair, PhD Medical Oncology SCE, Royal College, UK Ass. Professor of Clinical.

Slides:



Advertisements
Similar presentations
San Antonio Breast Cancer Symposia Authors: Dr. Sunil Verma Date posted: January 6 th, 2008.
Advertisements

1Kitasato-Harvard Symposium 10/03/2002 New Monoclonal Antibody Approved for Advanced Breast Cancer Shin-ichi Nihira, Ph.D. Dept. Clinical Research 3 Chugai.
First Efficacy Results of a Randomized, Open- Label, Phase III Study of Adjuvant Doxorubicin Plus Cyclophosphamide, Followed by Docetaxel with or without.
Integration of Taxanes in the Management of Breast Cancer
Xeloda X-panding options in the adjuvant treatment of breast cancer
Biomarker Analyses in CLEOPATRA: A Phase III, Placebo-Controlled Study of Pertuzumab in HER2- Positive, First-Line Metastatic Breast Cancer (MBC) Baselga.
Integration of Capecitabine into Anthracycline- and Taxane-Based Adjuvant Therapy for Triple Negative Early Breast Cancer: Final Subgroup Analysis of the.
William J. Gradishar MD, FACP Betsy Bramsen Professor of Breast Oncology Director, Maggie Daley Center For Women's Cancer Care Robert H. Lurie Comprehensive.
Updates from the San Antonio Breast Cancer Symposium 2013 HER2+ Breast Cancer Julie R. Gralow, M.D. Director and Jill Bennett Professor of Breast Medical.
Herceptin® (trastuzumab) in combination with chemotherapy: pivotal metastatic breast cancer survival data 1.
Cell Signaling Lecture 10. Receptor Tyrosine Kinases Regulate cell proliferation, differentiation, cell survival and cellular metabolism The signaling.
Memorial Sloan-Kettering Cancer Center
Fabio Puglisi Dipartimento di Oncologia Azienda Ospedaliero Universitaria di Udine Antiangiogenic Treatment Mediterranean School of Oncology.
Clinical Relevance of HER2 Overexpression/Amplification in Patients with Small Tumor Size and Node-Negative Breast Cancer Curigliano G et al. J Clin Oncol.
Adjuvant therapy for renal cell carcinoma Dr.Mina Tajvidi oncologist.
Round-Robin Review of HER2 Testing in the Context of Adjuvant Therapy for Breast Cancer (NCCTG N9831/BCIRG006/BCIRG005) 1 Concordance of HER2 Central Assessment.
A Meta Analysis of Risk of Cardiovascular Events in Patients with Metastatic Breast Cancer (MBC) Treated with Anti Vascular Endothelial Growth Factor (VEGF)
Drug Treatment of Metastatic Breast Cancer
6 months versus 12 months of adjuvant trastuzumab for patients with HER2- positive early breast cancer (PHARE): a randomised phase 3 trial Speaker: 陳鴻明.
Breast Plenary Abstracts How Do These Studies Impact Clinical Practice Today and in the Years Ahead? Presented By Eric Winer at 2014 ASCO Annual Meeting.
Gianni L et al. Proc SABCS 2012;Abstract GS6-7.
HERA: KEY DESIGN ELEMENTS, RESULTS AND FUTURE PLANS NSABP 17 SEPTEMBER 2005 Brian Leyland-Jones Minda De Gunzberg Professor of Oncology, McGill University,
Taxane-pretreated metastatic breast cancer (MBC): investigational agents TTP = median time to disease progression OS = median overall survival.
Van Cutsem E et al. ASCO 2009; Abstract LBA4509. (Oral Presentation)
OLD AND NEW ANTHACYCLINES: A STILL VALID OPTION IN BREAST CANCER TREATMENT True: Clara Natoli.
Should clinicians routinely recommend trastuzumab (Herceptin) as part of the adjuvant therapy for all patients with Her2 positive early breast cancer?
Herceptin ® : leading the way in metastatic breast cancer care Steffen Kahlert.
Assistant Professor of Medicine Dana-Farber Cancer Institute
The Use of Trastuzumab in the Elderly in the Adjuvant Setting and After Disease Progression in Patients with HER2-Positive Advanced Breast Cancer Dall.
Abstract Introduction  What is a Herceptin (Trastuzumab) ?  Herceptin (Trastuzumab) is an monoclonal antibody,it is an example of targeted therapy an.
HER2 POSITIVE BREAST CARCINOMA IN THE PRE AND POST ADJUVANT ANTI-HER-2 THERAPY ERA: A SINGLE ACADEMIC INSTITUTION EXPERIENCE IN THE SETTING OUTSIDE OF.
Herceptin ® adjuvant therapy: “a triumphal narrative of translational research” Brian Leyland-Jones McGill University Department of Oncology Montreal,
Sunil Verma MD, MSEd, FRCPC Medical Oncologist
1Bachelot T et al. Proc SABCS 2010;Abstract S1-6.
BASED ON PROTOCOL VERSION 1 SEPTEMBER 2012 A new study evaluating an investigational drug to treat patients with HER2-positive metastatic gastroesophageal.
Trastuzumab plus Adjuvant Chemotherapy for HER2-Positive Breast Cancer: Final Planned Joint Analysis of Overall Survival from NSABP B-31 and NCCTG N9831.
Terapia Neoadiuvante Revisione delle evidenze scientifiche
AVADO TRIAL David Miles Mount Vernon Cancer Centre, Middlesex, United Kingdom A randomized, double-blind study of bevacizumab in combination with docetaxel.
Lapatinib versus Trastuzumab in Combination with Neoadjuvant Anthracycline-Taxane-Based Chemotherapy: Primary Efficacy Endpoint Analysis of the GEPARQUINTO.
Cortés J et al. ASCO 2009; Abstract (Poster Discussion)
Baselga J et al. Proc SABCS 2010;Abstract S3-3.
HERA TRIAL: 2 Years versus 1 Year of Trastuzumab After Adjuvant Chemotherapy in Women with HER2-Positive Early Breast Cancer at 8 Years of Median Follow-Up.
Neoadjuvant Therapy in Her-2 Positive Breast Cancer
Responses to Subsequent Anti-HER2 Therapy After Treatment with Trastuzumab-DM1 in Women with HER2- Positive Metastatic Breast Cancer 1 A Phase Ib/II Trial.
Adjuvant therapy of HER2 positive early breast cancer The Evidences Antonio Frassoldati Oncologia Clinica - Ferrara.
A Phase III, Open-Label, Randomized, Multicenter Study of Eribulin Mesylate versus Capecitabine in Patients with Locally Advanced or Metastatic Breast.
Response-Guided Neoadjuvant Chemotherapy for Breast Cancer Gunter von Minckwitz, Jens Uwe Blohmer, Serban Dan Costa, Carsten Denkert, Holger Eidtmann Journal.
Annals of Oncology 24: 2206–2223, 2013 R3 조영학
PHASE II RANDOMIZED STUDY OF TRASTUZUMAB EMTANSINE VERSUS TRASTUZUMAB PLUS DOCETAXEL IN PATIENTS WITH HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 – POSITIVE.
Mothaffar F. Rimawi, Ingrid A. Mayer, Andres Forero, Rita Nanda, Matthew P. Goetz, Angel A. Rodriguez, Anne C. Pavlick, Tao Wang, Susan G. Hilsenbeck,
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer Slideset on: Piccart-Gebhart M, Procter M, Leyland- Jones B, et al. Trastuzumab.
Adjuvant and Neoadjuvant Therapy in Non- Small Cell Lung Cancer Seminars in Oncology 2oo5;32 (suppl 2):S9-S15 Kyung Hee Medical Center Department of Thoracic.
2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial Aron Goldhirsch, Richard.
PHARE Trial Results of Subset Analysis Comparing 6 to 12 Months of Trastuzumab in Adjuvant Early Breast Cancer Pivot X et al. Proc SABCS 2012;Abstract.
Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Joint Analysis.
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer José Baselga, M.D., Ph.D., Javier Cortés, M.D., Sung-Bae Kim, M.D., Seock-Ah Im,
Slamon D et al. SABCS 2009;Abstract 62.
A Single-Arm Phase IIIb Study of Pertuzumab and Trastuzumab with a Taxane as First-Line Therapy for Patients with HER2-Positive Advanced Breast Cancer.
Blackwell KL et al. SABCS 2009;Abstract 61
Swain SM et al. Proc SABCS 2012;Abstract P
Metastatic HER2+ Breast Cancer: Resistance
Neoadjuvant Therapy for HER2-Positive Breast Cancer
Her2-positive breast cancer: updating current best practice
Barrios C et al. SABCS 2009;Abstract 46.
Krop I et al. SABCS 2009;Abstract 5090.
Jones SE et al. SABCS 2009;Abstract 5082.
Untch M et al. Proc SABCS 2010;Abstract P
Reviewer: Dr. Sunil Verma Date posted: December 12th, 2011
Baselga J et al. SABCS 2009;Abstract 45.
Presentation transcript:

Neoadjuvant Target Therapy in Her-2 Positive Breast Cancer Dr. Khaled Abulkhair, PhD Medical Oncology SCE, Royal College, UK Ass. Professor of Clinical Oncology Mansoura University, Egypt

A long Road Searching for optimum Neo- Adjuvant Therapy in Her -2 Positive Breast Cancer What is the optimum Chemotherapy? What is the optimum Targeted Therapy? Did we reach the best available treatment?

Pertuzumab (Neo-Sphere), Dual blockade is active in the neoadjuvant setting yet Chemotherapy is still the corner stone. 29% 45.8 % 16.8 %. 24%

Searching For The Best….is a Continuous Efforts Every time they give us a car we believe it is the Safest, Fastest, and Strongest?

Taxanes…Late Nineties CMF… Anthracycline…1990 MTX…1951

Neoadjuvant Chemotherapy -Concept developed concurrently with adjuvant chemotherapy in the 1970s. -During the 1980s, several randomized and non-randomized studies were conducted to evaluate the worth of preoperative chemotherapy for operable breast cancer. -All of these studies demonstrated that preoperative chemotherapy results in a high rate of primary tumor response

Adjuvant OR Neoadjuvant Does the patient desire breast preservation? Is there a benefit from knowledge of in-vivo chemosensitivity? To investigate this, the NSABP and EORTC independently conducted clinical trials that compared neoadjuvant chemotherapy with adjuvant chemotherapy for patients with stage II or III disease. -Data published 2001, Both trials found that BCS rates were higher (22% BCS rate vs 8%) in the neoadjuvant arm due to down-staging of T3 disease.

Short Messages About Adjuvant Chemotherapy For Breast Cancer Review of the serial reports of the EBCTCG's meta- analyses. 1. Chemotherapy reduces the risk of recurrence and death. 2. Combination is more effective than single-agent. 3. Chemotherapy is more effective for women younger than 50 years of age than for older women. 4. Anthracyclines-containing regimens are more effective. 5. Six months of chemotherapy considered optimum. 6. Addition of Taxanes significantly improves RFS and OS.

Adding Docetaxel…Improved cCR…Improved pCR…Improved RFS...Improved OS in pCR

Neoadjuvant Before The Era of Targeted Therapy Neo-Adjuvant chemotherapy adds many advantages to the management of breast cancer. Anthracyclines are integral part in the neoadjuvant setting. Adding Taxanes to Anthracyclines boosts both DFS and OS. Weekly Paclitaxel is preferred over Q 3 weeks.

Effect of HER-2 amplification on breast cancer cells (Sinn, 1990). Human breast cancer cells Transfect with HER2 gene DNA synthesis  50–75% Cell growth rate  30–50% Growth in soft agar  225% expression of MMP-2. Metastatic potential  220% in nude mice Transformed Aggressive phenotype HER2 –ve HER2 +ve MCF-7 HER-2 Oncogene: overexpressed in 20-25% of breast cancers.. HER-2 Oncogene: overexpressed in 20-25% of breast cancers.. Tissue- specific expression of myc, ras, and HER-2 in mammary glands of transgenic mice has been shown to result in an increased incidence of both benign and malignant breast pathology (Sinn, 1990).

Biological Target…Her- Family

A New Story Began Searching for optimum Neo-Adjuvant Therapy in Her -2 Positive Breast Cancer Integrating Biological Agents? Which One is The Best? Did we reach the best available treatment?

Trastuzumab..…The Gold Standard Fast Trip from metastatic to neoadjuvant

Trastuzumab Trastuzumab is a humanized recombinant monoclonal antibody directed against HER-2 receptors. According to the international panel on neoadjuvant therapy, it should be part of the neoadjuvant treatment regimen in patients with HER-2 positive breast cancer. Many studies have shown that blockade of these receptors has therapeutic implications (Zhang et al., 1999). Furthermore, these antibodies have synergistic interactions with cytotoxic agents, such as the anthracyclines, the platinum analogs, and the taxanes (Baselga et al., 1994).

Trastuzumab in the adjuvant setting produced spectacular results with about 50% decrease in recurrence as shown in 6 randomized trials. After follow-ups ranging from 1 to 2 1/2 years, five trials (NSABP B- 31, N9831, BCIRG006, FinHER and HERA) demonstrated such marked benefit that the trials were stopped and the results reported. Trastuzumab-treated patients had about a 46% to 58% reduction in risk of recurrence in these five trials. Significant survival benefits have emerged in five of the six trials, with a 33% to 59% reduction in mortality.

Lapatinib Lapatinib is an orally active, small molecule which reversibly inhibits HER1 and HER2 tyrosine kinase. This inhibition leads to blockade of different signaling pathways, resulting in growth arrest and/or apoptosis. Some data indicate that lapatinib can also block HER2-HER3 mediated cell growth [22, 23]. Lapatinib as a small molecule can penetrate the blood-brain barrier and, therefore, was claimed for therapy and prevention of brain metastases.

Pertuzumab Pertuzumab is the humanized monoclonal antibody that binds to dimerization domain II of HER-2 receptor, which is necessary for HER-2 activation and cell signaling. Clinically, the most important action of Pertuzumab is inhibition of HER2-HER3 dimerization. Pertuzumab affects important signaling pathways that mediate cell proliferation and synergistically with Trastuzumab inhibits breast tumor cells survival.

Which Regimen Is The Best? A number of chemotherapy + Trastuzumab combinations have proven good response rates with good tolerability. However, several aspects have yet to be clearly defined: Which regimen has superior efficacy? if Anthracyclines should be used or not; and if they should only be used sequentially or also concurrently with Trastuzumab? Sequential Anthracycline - Taxanes plus Trastuzumab gives a pCR of 40% versus 17% with chemotherapy alone. New era began with the Dual HER-2 blockade?

Trastuzumab In The Neoadjuvant Setting In the first reported randomized trial, Buzdar et al 2005, evaluated patients with HER2-positive, early-stage operable breast cancer, who were assigned to receive FECx4 with or without Trastuzumab weekly. Adding Trastuzumab to neoadjuvant therapy significantly increased the pCR rate from 26.3% to 65.2%. These results led to a premature closure of the study. Unfortunately, such high pCR rates have not been observed in successive trials. The Neoadjuvant Herceptin (NOAH) trial, 2010, found that adding Trastuzumab significantly improved overall response rate (ORR) (87% versus 74%; = 0.009) and pCR rate (43% versus 22%; = ).

The famous German (GeparQuattro) trial, 2010 which included 1509 patients with either locally advanced (T3 or T4), any hormonal status but lymph-node-positive tumours. EC X 4 Trastuzumab for 1-Year in Her-2 Positive SURGERYSURGERY A B C Docetaxel (100mg/m2) x4 Docetaxel (75mg/m2) + Capecitabine (1800mg/m2) x4 Docetaxel (75mg/m2) x4 followed by capecitabine (1800mg/m2) x4 31%.16%. TRASTUZUMAB For HER+++

(TECHNO), 2011 Taxol Epirubicin Cyclophosphamide Herceptin NeOadjuvant study multicentre, prospective, open-label, phase II clinical trial enrolled 217. The primary endpoint was pCR. A 39 % had pCR. With significant better 3 year DFS and OS in the group of pCR. A systematic review and meta-analysis, 2011 concluded that the use of Trastuzumab combined with neoadjuvant chemotherapy in patients with HER2-positive breast cancer seems to offer substantial benefit in terms of pCR. EC X 4 Paclitaxel 175 mg/m2 Q3W + Trastuzumabx4 Trastuzumab to complete 1 year Surgery

Dual Blockade in Neoadjuvant Setting (Neo-Sphere), Adding Pertuzumab to Trastuzumab is active and substantially increases the pCR 29% 45.8 % 16.8 %. 24% 27%.

Dual Blockade in Neoadjuvant Setting (NeoALTTO) trial, 2012 included 455 HER2-positive patients who had tumours at least 2 cm in diameter. Combination of lapatinib and Trastuzumab led to a significantly higher pCR rate (51.3%) than that of the monotherapy arms. The response to lapatinib was numerically lower than to Trastuzumab, although the difference did not reach statistical significance. The dual combination was associated with higher toxicity, especially diarrhoea and hepatotoxicity, and more patients discontinued therapy because of adverse events.

The comparison of Lapatinib versus Trastuzumab was the aim of the GeparQuinto trial, 2012 This randomized phase III study included 620 patients with operable or locally advanced HER2-positive breast cancer. The results have confirmed a higher pCR rate for the Trastuzumab arm (30.3%) compared with that of lapatinib (22.7%).

The primary endpoint of cardiac safety was met, with a low incidence of left ventricular systolic dysfunction across all arms. pCR rates were similar across the three arms and regardless of the chemotherapy chosen reached from 57% to 66% with DCTP. Better results were seen in patients with hormone- negative disease. Trastuzumab plus Pertuzumab in Neoadjuvant HER2- Positive Breast Cancer trial (TRYPHAENA), 2013.

The efficacy of pCR as a measure of evaluating therapies for breast cancer has been a closely watched issue in oncology drug development. In September 2013, the FDA approved an expanded indication for Pertuzumab in combination with Trastuzumab (Herceptin) and Docetaxel preoperatively in patients with high risk, HER2 positive early stage breast cancer. The decision marked the first time that the FDA has formally approved a neoadjuvant breast cancer treatment. A meta-analysis by Cortazar et al,2014 showed that achieving pCR following preoperative chemotherapy was an especially strong predictor of event free survival in aggressive forms of breast cancer. Attaining pCR reduced the risk of death by 92% in cancers that were HER2 positive and hormone receptor–negative cancers and by 84% in (TNBCs).

Comparative Effectiveness of Neoadjuvant Therapy for HER2–Positive Breast Cancer: A Network Meta-Analysis In a recent meta-analysis published JNCI J Natl Cancer Inst (2014). Evaluating a total of 10 eligible trials including 2247 patients in seven different treatment arms were assessed. Chemotherapy +\- Anti-HER-2 agents that included Trastuzumab, Lapatinib, and Pertuzumab. This study indicates that combining two anti-HER-2 agents with Chemotherapy is the most effective treatment modality in the neoadjuvant setting for HER-2 positive breast cancer.

Value of pCR in HER2-Positive Breast Cancer Studies showed that pCR means better DFS, OS and lower relapse rate. pCR is considered a surrogate marker for outcome in HER-2. However, value of pCR differs according to the hormonal status. The MDACC group, 2006 detected ER-negative is associated with higher pCR rates, regardless of type and duration of chemotherapy. It is still true for target therapy too. A recent analysis, 2011 also showed that pCR was associated with significantly higher DFS only in hormone negative but not in hormone positive disease. Accordingly, we have to be careful in using pCR as a marker in the case of hormone positive Her-2 positive disease..

Efforts to Omit Anthracyclines Feasible and can decrease the toxicity supported by series of phase II neoadjuvant studies that reported pCR rates ranging from 19% to 76% using Trastuzumab, a Taxanes, and a platinum compound and supported by results of TCH/DCTP. TRYPHAENA supported omitting Anthracyclines. However, the BCIRG 006 study demonstrated in the adjuvant setting a slightly inferior disease-free survival for the TCH against ACTH regimen.

Conclusions HER-2 disease presents a heterogeneous group of diseases. Its management has significantly improved in recent years, and neoadjuvant treatment has become widely accepted. Neoadjuvant Trastuzumab had a substantial impact on the outcome of this disease. Dual blockade has revealed significant efficacy and presents a new therapeutic approach. Yet, cost is an important issue beside confirming OS benefits. Guidelines for management of Her-2 positive MBC is rapidly changing due to availability of many new targeted agents e.g. TDM-1, Neratinib, Afatinib….. Concurrent Anthracyclines Trastuzumab looks feasible with accepted toxicity. Would this apply to Our patients? Middle East Western

Now, Do We Have The Fastest, Safest and Strongest? I believe we did not reach the best yet. How to accurately define those who will be pCR?